Please assess the completion status of the following clinical trial:

Trial Title: Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of persistent asthma for at least one year~* History of asthma treatments including as-needed inhaled short-acting beta-agonists (albuterol/salbutamol); stable doses of inhaled corticosteroids (ICS), combination ICS/long-acting (inhaled) Beta2-adrenergic agonist (LABA) and/or oral asthma controller(s)~* Must be able to discontinue or taper asthma controlling medications while receiving Montelukast~* No history of smoking or no smoking for at least 1 year, with a smoking history of no more than 10 pack-years~* Body Mass Index (BMI) of 15 kg/m\^2 to 40 kg/m\^2.~* Females must not be pregnant (negative serum human chorionic gonadotropin test) or breastfeeding and must not plan to become pregnant for the duration of the study, including the post-treatment follow-up period~* Women and male participants of reproductive potential must agree to use adequate contraception for the duration of the study~Exclusion Criteria:~* Evidence of another active pulmonary disorder such as bronchiectasis or chronic obstructive pulmonary disease (COPD)~* Unable to perform acceptable, repeatable spirometry~* History of myocardial infarction, congestive heart failure, or uncontrolled cardiac arrhythmia within 3 months of screening visit~* Major surgical procedure(s) within 4 weeks of screening visit~* Blood donation within 2 weeks of screening visit~* Treatment in an emergency room for asthma (within 4 weeks) or hospitalization for asthma or respiratory condition within 2 months of screening visit~* Evidence of active sinus disease within 2 weeks of screening visit~* Upper respiratory infection (viral or bacterial) within 1 month of screening visit~* History of a psychiatric disorder within 3 months of screening visit~* History of human immunodeficiency virus (HIV)~* Unstable disease of the ophthalmologic, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematologic systems~* History of cancer (except for successfully treated basal and squamous cell carcinomas of the skin) within 5 years of screening visit~* Uncontrolled hypertension~* Participation in a clinical trial involving an investigational drug within 4 weeks of screening visit~* Hypersensitivity or intolerance to inhaled beta-agonists and/or leukotriene inhibitors or any of their ingredients, including lactose and galactose~* Known sensitivity to or has not had previous exposure to aspirin or non-steroidal anti-inflammatory drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-1029 150 mg + Montelukast 10 mg (Type: EXPERIMENTAL): Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
- MK-1029 Placebo + Montelukast 10 mg (Type: PLACEBO_COMPARATOR): Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete